Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Johnson & Johnson Enterprise Innovation Inc.
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Moores Cancer Center at UC San Diego Health | La Jolla, California, United States | Recruiting |
| University of Connecticut Health Center | Farmington, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
| Emory University Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Washington University in St Louis | St Louis, Missouri, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06667908